Collegium Pharmaceutical Inc (COLL) : Monashee Investment Management reduced its stake in Collegium Pharmaceutical Inc by 85.29% during the most recent quarter end. The investment management company now holds a total of 10,000 shares of Collegium Pharmaceutical Inc which is valued at $124,000 after selling 58,000 shares in Collegium Pharmaceutical Inc , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.Collegium Pharmaceutical Inc makes up approximately 0.19% of Monashee Investment Management’s portfolio.
Other Hedge Funds, Including , California State Teachers Retirement System boosted its stake in COLL in the latest quarter, The investment management firm added 12,258 additional shares and now holds a total of 28,395 shares of Collegium Pharmaceutical Inc which is valued at $352,098.Tocqueville Asset Management boosted its stake in COLL in the latest quarter, The investment management firm added 8,000 additional shares and now holds a total of 51,900 shares of Collegium Pharmaceutical Inc which is valued at $629,547. Collegium Pharmaceutical Inc makes up approx 0.01% of Tocqueville Asset Management’s portfolio. Barrett Asset Management sold out all of its stake in COLL during the most recent quarter. The investment firm sold 277 shares of COLL which is valued $3,360. Bnp Paribas Arbitrage Sa added COLL to its portfolio by purchasing 530 company shares during the most recent quarter which is valued at $6,752.
Collegium Pharmaceutical Inc (COLL) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $12.05 and reached the intraday high at $12.2. The bulls started the profit booking and pushed the shares to intraday low of $11.9. The trading session was marked by a volume range of 52,830 shares exchanging hands. The 52-week high of the shares is $30.58 and the 52-week low is $11.31. The market cap of the company stands at $283 M and there are 2,35,27,454 shares in public circulation.
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate Xtampza ER (Xtampza) is an abuse-deterrent extended-release oral formulation of oxycodone opioid medication. Xtampza has the same active ingredient as OxyContin OP which is the abuse-deterrent extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing crushing and/or dissolving Xtampza and then taking it orally or smoking snorting or injecting it did not change its drug release profile.